Financials data is unavailable for this security.
View more
Year on year TOT BIOPHARM International Co Ltd has grown net income from a loss of -49.92m to a smaller loss of -37.76m primarily through revenue growth (442.18m to 780.63m). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 76.54% growth in revenues contributed enough to still see net income improve.
Gross margin | 72.02% |
---|---|
Net profit margin | 0.92% |
Operating margin | 1.52% |
Return on assets | 0.64% |
---|---|
Return on equity | 1.25% |
Return on investment | 0.84% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at TOT BIOPHARM International Co Ltd fell by 66.17m. However, the company earned 56.43m from its operations for a Cash Flow Margin of 7.23%. In addition the company generated 38.23m cash from financing while 164.11m was spent on investing.
Cash flow per share | 0.0964 |
---|---|
Price/Cash flow per share | 22.12 |
Book value per share | 1.03 |
---|---|
Tangible book value per share | 1.02 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.94 |
---|---|
Quick ratio | 1.63 |
Total debt/total equity | 0.5303 |
---|---|
Total debt/total capital | 0.3465 |
More ▼